Browsing Category
Pharma Industry News
4724 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Ascletis Pharma advances ASC36 into clinical development, betting on oral amylin peptides for obesity
Ascletis Pharma Inc. moves ASC36 into clinical development, signalling a strategic push into oral amylin peptides for obesity. Find out what this means next.
Lunai Bioworks (NASDAQ: LNAI) tests whether AI-driven patient stratification can de-risk oncology trials
Find out how Lunai Bioworks Inc. is using AI to uncover hidden survival signals in oncology trials and what it could mean for future FDA approvals.
AKEEGA moves upstream as CHMP backs PARP inhibition in metastatic hormone-sensitive prostate cancer
Find out how CHMP support for AKEEGA could shift PARP inhibitors into earlier prostate cancer treatment and reshape precision oncology strategy.
Can detox-focused nutraceuticals sustain credibility as Anathapindika Health grows retail presence
Find out whether detox-focused nutraceuticals can maintain credibility as Anathapindika Health expands into specialty retail stores.
How intranasal delivery could reshape Clearmind Medicine Inc.’s MEAI development strategy in addiction
Find out how Clearmind Medicine Inc.’s intranasal MEAI strategy could reshape addiction drug development risk and execution.
How real-world evidence and pediatric studies may determine BRIUMVI’s ceiling in relapsing multiple sclerosis
Find out how real-world data and pediatric studies could define the long-term ceiling for TG Therapeutics’ BRIUMVI in relapsing multiple sclerosis.
NeuroSense Therapeutics (NASDAQ: NRSN) extends PrimeC exclusivity to 2042 with Australian patent as Phase 3 focus intensifies
Find out how NeuroSense Therapeutics’ Australian patent grant strengthens PrimeC’s long-term outlook as the ALS program advances toward Phase 3.
Lumosa Therapeutics reports Phase 2 functional gains for LT3001 in disabling acute ischemic stroke
Lumosa Therapeutics’ LT3001 Phase 2 stroke data show functional gains beyond standard windows. Find out what this means for Phase 3 and investors.
How orphan drug status and patent protection shape Ampligen’s commercial and regulatory outlook
Discover how orphan drug status and long-dated patents could shape Ampligen’s regulatory path and commercial value in pancreatic cancer.
How a proenzyme-based approach from Propanc Biopharma tests the limits of current solid tumor paradigms
Can a proenzyme therapy reshape solid tumor treatment models? Explore what Propanc Biopharma’s PRP strategy signals for oncology markets.